ES2655492T3 - Formulaciones que comprenden cloruro de metiltioninio - Google Patents

Formulaciones que comprenden cloruro de metiltioninio Download PDF

Info

Publication number
ES2655492T3
ES2655492T3 ES11802119.5T ES11802119T ES2655492T3 ES 2655492 T3 ES2655492 T3 ES 2655492T3 ES 11802119 T ES11802119 T ES 11802119T ES 2655492 T3 ES2655492 T3 ES 2655492T3
Authority
ES
Spain
Prior art keywords
mtc
tablets
tablet
dissolution
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11802119.5T
Other languages
English (en)
Spanish (es)
Inventor
Karrar Ahmad Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Application granted granted Critical
Publication of ES2655492T3 publication Critical patent/ES2655492T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES11802119.5T 2010-11-30 2011-11-30 Formulaciones que comprenden cloruro de metiltioninio Active ES2655492T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41816410P 2010-11-30 2010-11-30
US418164P 2010-11-30
PCT/GB2011/001662 WO2012072977A2 (en) 2010-11-30 2011-11-30 Compound formulations

Publications (1)

Publication Number Publication Date
ES2655492T3 true ES2655492T3 (es) 2018-02-20

Family

ID=45418703

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11802119.5T Active ES2655492T3 (es) 2010-11-30 2011-11-30 Formulaciones que comprenden cloruro de metiltioninio

Country Status (10)

Country Link
US (1) US9192611B2 (enExample)
EP (1) EP2645994B1 (enExample)
JP (1) JP6093707B2 (enExample)
CN (1) CN103379901B (enExample)
AU (1) AU2011334679B2 (enExample)
CA (1) CA2818068C (enExample)
ES (1) ES2655492T3 (enExample)
MY (1) MY163074A (enExample)
SG (2) SG10201602111VA (enExample)
WO (1) WO2012072977A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014153444A (ja) * 2013-02-06 2014-08-25 Konica Minolta Inc 位相差フィルム、偏光板及び液晶表示装置
PT3487505T (pt) 2016-07-25 2023-06-07 Wista Lab Ltd Administração e dosagem de diaminofenotiazinas
FR3104438B1 (fr) 2019-12-12 2021-11-19 Univ Bordeaux Formulation pour le bleu de methylene et procede
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
EP4590275A1 (en) 2022-09-21 2025-07-30 WisTa Laboratories Ltd. Novel formulations and vehicles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
JPH0840942A (ja) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 薬物放出制御製剤
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
ES2409683T3 (es) 2004-09-23 2013-06-27 Wista Laboratories Ltd. Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
EA012220B1 (ru) * 2004-10-19 2009-08-28 Крка, Товарна Здравил, Д. Д., Ново Место Твёрдая фармацевтическая композиция, содержащая донепезила гидрохлорид
WO2007024961A2 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
DE602006006536D1 (de) * 2006-01-05 2009-06-10 Teva Pharma Trockene Aripiprazolformulierungen
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
DK2205245T3 (en) 2007-10-03 2015-09-28 Wista Lab Ltd Therapeutic use of diaminophenothiaziner
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
BR112012006626B8 (pt) * 2009-09-24 2021-05-25 Wista Lab Ltd processo para a preparação da forma a pentahidratada e método da secagem da forma a pentahidratada de mtc

Also Published As

Publication number Publication date
JP2013544272A (ja) 2013-12-12
EP2645994A2 (en) 2013-10-09
JP6093707B2 (ja) 2017-03-08
MY163074A (en) 2017-08-15
CN103379901B (zh) 2018-04-03
AU2011334679A1 (en) 2013-07-18
US9192611B2 (en) 2015-11-24
CA2818068A1 (en) 2012-06-07
EP2645994B1 (en) 2017-11-01
SG10201602111VA (en) 2016-04-28
CN103379901A (zh) 2013-10-30
AU2011334679B2 (en) 2016-12-15
WO2012072977A8 (en) 2012-09-20
US20130243858A1 (en) 2013-09-19
CA2818068C (en) 2019-06-11
WO2012072977A2 (en) 2012-06-07
WO2012072977A3 (en) 2012-08-16
SG190406A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
KR102508739B1 (ko) Magl 억제제의 결정형
EP2842549B1 (en) Orally disintegrating tablet and method for producing same
RU2690685C2 (ru) Фармацевтические композиции, содержащие алпелисиб
Abdelmonem et al. Formulation and evaluation of baclofen-meloxicam orally disintegrating tablets (ODTs) using co-processed excipients and improvement of ODTs performance using six sigma method
Alvarado et al. In vitro biopharmaceutical equivalence of carbamazepine sodium tablets available in Lima, Peru
Sutradhar et al. Formulation and evaluation of taste masked oral dispersible tablets of domperidone using sublimation method
ES2377552T3 (es) Composiciones disueltas fácilmente y estables de candesartán cilexetilo preparadas con una granulación por vía húmeda
US9192611B2 (en) Formulations comprising methylthioninium chloride
Kumar et al. Formulation and evaluation of piroxicam fast dissolving tablets using direct compression and sublimation method
ES2403193T3 (es) Composiciones que comprenden alprazolam para el tratamiento del insomnio primario y del insomnio asociado con estados de ansiedad y procedimientos para su preparación
Kumar et al. Development and characterization of melt-in-mouth tablets of haloperidol by sublimation technique
Sharma et al. A Review on Fast Dissolving Tablets
Buwade et al. Advantages of immediate release tablets over the other tablet forms
Wanare et al. Formulation and evaluation of fast dissolving tablets of azithromycin dihydrate using different super disintegrants
Durge et al. Formulation Development and Characterization of Anti-Retroviral Agents
Rawat et al. FORMULATION, DEVELOPMENTAND EVALUATION OF SUSTAINDED-RELEASE TABLET OF DOXOPHYLLINE
Chimombe et al. Orally disintegrating tablets: formulation, preparation, Evaluation and Recent Advances: A
ES2863402T3 (es) Combinación de plantas oficinales y su uso en el tratamiento y/o prevención de trastornos del sueño
Rana et al. The formulation and evaluation of mouth dissolving tablet Levocetirizine by using synthetic Superdisintegrants
Paškevičiūtė et al. OF DICLOFENAC SODIUM CAPSULES
Zin et al. Preliminary Study on the Formulation of Syariah Compliant Generic Sustained Release Gliclazide Tablet Using Xanthan Gum
Seshadri et al. Formulation and characterization of mouth dissolving tablets containing benzodiazepine
HK1184386B (en) Formulations comprising methylthioninium chloride
HK1184386A (en) Formulations comprising methylthioninium chloride
ES2422657B1 (es) Composición farmacéutica sólida de cilostazol